Development of dermatomyositis in patients on biologic therapy: A systematic review - 09/12/21
Doi : 10.1016/j.jaad.2021.01.087
Asfandyar Mufti, MD a, Khalad Maliyar, BA b, Nadia Kashetsky, MSc c, Muskaan Sachdeva, BHSc b, Jensen Yeung, MD, FRCPC a, ⁎ 
a Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
b Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
c Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada
∗Correspondence to: Jensen Yeung, MD, FRCPC, Department of Dermatology, Women's College Hospital, 76 Grenville St, Fifth Floor, Toronto, ON M5S 1B2, CanadaDepartment of DermatologyWomen's College Hospital76 Grenville St, Fifth FloorTorontoONM5S 1B2Canada
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2021
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 86 - N° 1
P. 218-221 - janvier 2022 Retour au numéro
Article précédent
- Psoriasis and risk of cutaneous melanoma: A retrospective, comparative, registry-based cohort study
- Sam Polesie, Martin Gillstedt
- Cutaneous Epstein-Barr virus–positive diffuse large B-cell lymphoma, not otherwise specified: A systematic review and comparative analysis with Epstein-Barr virus–negative, leg type
- Joon Min Jung, Hyoung Min Na, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Woo Jin Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?